Position in ABVX
as of Jun 30, 2026
· filed Aug 4, 2026
Position Value
$2,258,490
-$5,040,279 QoQ
Shares Held
16,948
-74.1% QoQ
Ownership
0.019%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#143
of 301 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ABVX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026TD Asset Management Inc holds $1,129,937,988 across 119 Biotechnology names. ABVX ranks #70 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
259,317 | $161,694,522 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
207,960 | $103,299,970 | |
| 3 | HALO |
Halozyme Therapeutics, Inc.
|
1,115,730 | $87,328,187 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
233,696 | $70,349,506 | |
| 5 | CYTK |
Cytokinetics Inc
|
385,130 | $32,809,224 | |
| 6 | RPRX |
Royalty Pharma plc
|
567,497 | $31,819,556 | |
| 7 | ASND |
Ascendis Pharma A/S
|
119,085 | $31,762,351 | |
| 8 | KYMR |
Kymera Therapeutics, Inc.
|
272,900 | $31,293,443 |
All Filings in ABVX
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,258,490 | 16,948 | Shares | Sole | 2026-08-04 | |
| 2026-03-31 | $7,298,769 | 65,548 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $8,617,504 | 63,902 | Shares | Sole | 2026-02-10 | |
| 2025-09-30 | $3,946,661 | 46,486 | Shares | Sole | 2025-11-10 | |
| No filing history on record for this holder in this stock. | ||||||